almagate has been researched along with Macular Edema in 65 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 15 (23.08) | 29.6817 |
2010's | 50 (76.92) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Evans, JR; Gordon, I; Lucenteforte, E; Parravano, M; Virgili, G | 2 |
Duvnjak, L; Ljubić, S; Poljičanin, T; Tomić, M; Vrabec, R | 1 |
Li, M; Qian, T; Wan, Y; Xu, X; Zhao, M | 1 |
Enaida, H; Ishibashi, T; Nakao, S; Yoshida, S | 1 |
Brillante, C; De Paolis, G; Impallara, D; La Torre, G; Malarska, K; Muscella, R; Pacella, E; Pacella, F; Smaldone, G; Turchetti, P | 1 |
García-Campos, JM; López-Gálvez, MI | 1 |
Colby, JA; Ollendorf, DA; Pearson, SD | 1 |
Badaró, E; Falabella, P; Farah, ME; Koss, M; Maia, M; Stefanini, FR | 1 |
Braithwaite, T; Greenberg, PB; Lindsley, K; Nanji, AA | 1 |
Chong, NV; Morjaria, R | 1 |
Huang, P; Song, Z; Sun, X | 1 |
Loftus, J; Scanlon, PH; Starita, C; Stratton, IM | 1 |
Takamura, Y | 1 |
Esaka, E; Ishibashi, T; Ishida, S; Isogawa, N; Ohji, M; Yoshimura, N; Yuzawa, M | 1 |
Kobayashi, M; Manabe, S; Ono, A; Shiraga, F; Shiragami, C; Yamashita, A | 1 |
Evans, JR; Menchini, F; Parravano, M; Virgili, G | 1 |
Bakri, SJ; Ehlers, JP; Ho, AC; Kim, SJ; Schoenberger, SD; Thorne, JE; Yeh, S | 1 |
Ehrlich, R; Harris, A; Hussain, RM; Prall, R; Siesky, B; Yung, CW | 1 |
Colucciello, M | 1 |
Barner, JC; Jiang, S; Ling, YL; Park, C | 1 |
Bandello, F; Cicinelli, MV; Parodi, MB | 1 |
Ajlan, RS; Silva, PS; Sun, JK | 1 |
Amselem, L; Cervera, E; Diaz-Llopis, M; Huste, F; Montero, J; Salom, D | 1 |
Angulo Bocco, MC; Coscas, G; Glacet-Bernard, A; Soubrane, G; Zourdani, A | 1 |
Bhisitkul, RB; Fung, AE | 1 |
Giuliari, GP; Gonzalez, VH; Guel, DA | 1 |
Do, DV; Khurana, RN; Nguyen, QD | 1 |
Adamis, AP; Altaweel, MM; Buggage, RR; Cunningham, ET; Goldbaum, M; Guyer, DR; Katz, B; Wells, JA; Wroblewski, JJ | 1 |
Díaz-Llopis, M; Francés, E; Gallego-Pinazo, R; Gómez-Maestra, M; López-Lizcano, R; Udaondo, P | 1 |
Díaz-Llopis, M; Francés, E; Gallego-Pinazo, R; Gómez, MJ; López, R | 1 |
DaCosta, J; Salam, A; Sivaprasad, S | 1 |
Bux, AV; Iaculli, C; Martinelli, D; Noci, ND; Querques, G | 1 |
Menchini, F; Parravano, M; Virgili, G | 1 |
Gonzales, CR; Wells, JA; Wroblewski, JJ | 1 |
Cohen, SY; Nghiem-Buffet, S | 1 |
Chan, C; Koo, S; Wong, I | 1 |
Cortez, MA; Cortez, RT; Giuliari, GP; Guel, DA | 1 |
Gelisken, F; Ziemssen, F | 1 |
Bandello, F; Battaglia Parodi, M; Iacono, P | 1 |
Joussen, AM; Kakkassery, V; Winterhalter, S | 1 |
Braithwaite, T; Greenberg, PB; Nanji, AA | 1 |
Dombi, T; Ice, KS; Loftus, J; Sultan, MB; Zhou, D | 1 |
Coney, JM; Hornik, JH; Miller, DG; Schartman, JP | 1 |
Loftus, JV; Pleil, AM; Sultan, MB | 1 |
Grabska-Liberek, I; Jamrozy-Witkowska, A; Jankowska-Lech, I; Kowalska, K; Nowosielska, A; Terelak-Borys, B | 1 |
Arévalo, JF; Díaz-Llopis, M; Dolz-Marco, R; Gallego-Pinazo, R; García-Delpech, S; Udaondo, P | 1 |
Huic, M; Zechmeister-Koss, I | 1 |
Bux, AV; Iaculli, C; Noci, ND; Querques, G | 1 |
Fraser-Bell, S; Gillies, M; Salem, W | 1 |
Chiosi, F; Costagliola, C; dell'Omo, R; Mastropasqua, R; Parmeggiani, F; Rinaldi, M; Romano, MR; Semeraro, F | 1 |
Stewart, MW | 1 |
Chong, V | 1 |
Lang, GE | 1 |
O'Malley, PG | 1 |
Bandello, F; Battaglia Parodi, M; Berchicci, L; Iacono, P; La Spina, C | 1 |
Brown, GC; Brown, MM; Ho, AC; Ip, MS; Kim, SJ; Recchia, FM; Scott, IU | 1 |
Brunetti, M; Menchini, F; Parravano, M; Virgili, G | 1 |
Lai, G; Lloyd, AJ; Loftus, J; Pleil, A; Turner, M | 1 |
Huber, S; Kieselbach, GF; Kirchmair, R; Kralinger, MT; Zehetner, C | 1 |
Adamis, AP; Aiello, LP; Altaweel, M; Bressler, NM; Cunningham, ET; D'Amico, DJ; Goldbaum, M; Guyer, DR; Katz, B; Patel, M; Schwartz, SD | 1 |
Adamis, AP; Altaweel, M; Barrett, K; Bressler, NM; Cunningham, ET; Davis, MD; Goldbaum, M; Gonzales, C; Guyer, DR; Patel, M | 1 |
Adamis, AP; Ng, EW | 1 |
Iaculli, C; Noci, ND; Prascina, F; Querques, G | 1 |
Cervera, E; Diaz-Llopis, M; Garcia-Delpech, S; Udaondo, P | 1 |
32 review(s) available for almagate and Macular Edema
Article | Year |
---|---|
Anti-vascular endothelial growth factor for diabetic macular oedema: a network meta-analysis.
Topics: Angiogenesis Inhibitors; Aptamers, Nucleotide; Bevacizumab; Diabetic Retinopathy; Humans; Laser Coagulation; Macular Edema; Network Meta-Analysis; Quality of Life; Randomized Controlled Trials as Topic; Ranibizumab; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Triamcinolone; Vascular Endothelial Growth Factor A; Visual Acuity | 2017 |
Diabetic Macular Edema: Traditional and Novel Treatment
Topics: Angiogenesis Inhibitors; Aptamers, Nucleotide; Bevacizumab; Dexamethasone; Diabetic Retinopathy; Glucocorticoids; Humans; Intravitreal Injections; Laser Coagulation; Macular Edema; Practice Guidelines as Topic; Ranibizumab; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Tomography, Optical Coherence; Vascular Endothelial Growth Factor A; Visual Acuity; Vitrectomy | 2017 |
Anti-vascular endothelial growth factor for diabetic macular oedema: a network meta-analysis.
Topics: Angiogenesis Inhibitors; Aptamers, Nucleotide; Bevacizumab; Diabetic Retinopathy; Humans; Laser Coagulation; Macular Edema; Network Meta-Analysis; Quality of Life; Randomized Controlled Trials as Topic; Ranibizumab; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Triamcinolone; Vascular Endothelial Growth Factor A; Visual Acuity | 2018 |
Comparison of the efficacy and safety of drug therapies for macular edema secondary to central retinal vein occlusion.
Topics: Adrenal Cortex Hormones; Aptamers, Nucleotide; Dexamethasone; Humans; Intraocular Pressure; Intravitreal Injections; Macular Edema; Network Meta-Analysis; Randomized Controlled Trials as Topic; Ranibizumab; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Retinal Vein Occlusion; Risk Assessment; Treatment Outcome; Triamcinolone; Vascular Endothelial Growth Factor A | 2018 |
[From scientific evidence to clinical practice: treatment protocols for diabetic macular edema].
Topics: Algorithms; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Clinical Protocols; Diabetic Retinopathy; Drug Approval; European Union; Fluorescein Angiography; Humans; Laser Coagulation; Macular Edema; Microscopy, Acoustic; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; Ranibizumab; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Tomography, Optical Coherence; Translational Research, Biomedical; Triamcinolone Acetonide; Vascular Endothelial Growth Factor A | 2012 |
Comparative effectiveness of anti-VEGF agents for diabetic macular edema.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Comparative Effectiveness Research; Diabetic Retinopathy; Humans; Macular Edema; Ranibizumab; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Vascular Endothelial Growth Factor A | 2013 |
Anti-VEGF for the management of diabetic macular edema.
Topics: Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Clinical Trials as Topic; Diabetic Retinopathy; Gene Expression; Humans; Intravitreal Injections; Light Coagulation; Macular Edema; Ranibizumab; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Vascular Endothelial Growth Factor A | 2014 |
Anti-vascular endothelial growth factor for macular oedema secondary to central retinal vein occlusion.
Topics: Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Humans; Macular Edema; Randomized Controlled Trials as Topic; Ranibizumab; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Retinal Vein Occlusion; Vascular Endothelial Growth Factor A | 2014 |
Pharmacokinetic evaluation of pegaptanib octasodium for the treatment of diabetic edema.
Topics: Animals; Aptamers, Nucleotide; Cardiovascular Diseases; Diabetic Retinopathy; Humans; Macular Degeneration; Macular Edema; Risk Factors; Vascular Endothelial Growth Factor A; Vision Disorders | 2014 |
Anti-vascular endothelial growth factor for diabetic macular oedema.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Diabetic Retinopathy; Humans; Laser Coagulation; Macular Edema; Randomized Controlled Trials as Topic; Ranibizumab; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Triamcinolone; Vascular Endothelial Growth Factor A | 2014 |
Therapies for macular edema associated with central retinal vein occlusion: a report by the American Academy of Ophthalmology.
Topics: Academies and Institutes; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Databases, Factual; Drug Therapy, Combination; Glucocorticoids; Humans; Intravitreal Injections; Laser Coagulation; Macular Edema; Ophthalmology; Ranibizumab; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Retinal Vein Occlusion; Technology Assessment, Biomedical; Treatment Outcome; Vascular Endothelial Growth Factor A; Visual Acuity | 2015 |
Current intravitreal pharmacologic therapies for diabetic macular edema.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Diabetic Retinopathy; Glucocorticoids; Humans; Intravitreal Injections; Macular Edema; Ranibizumab | 2015 |
Anti-VEGF Molecules for the Management of Diabetic Macular Edema.
Topics: Aptamers, Nucleotide; Bevacizumab; Diabetic Retinopathy; Humans; Macular Edema; Randomized Controlled Trials as Topic; Ranibizumab; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Treatment Outcome; Vascular Endothelial Growth Factor A; Visual Acuity | 2015 |
Vascular Endothelial Growth Factor and Diabetic Retinal Disease.
Topics: Angiogenesis Inhibitors; Aptamers, Nucleotide; Bevacizumab; Diabetic Retinopathy; Humans; Intravitreal Injections; Macular Edema; Ranibizumab; Vascular Endothelial Growth Factor A | 2016 |
Pegaptanib sodium for the treatment of proliferative diabetic retinopathy and diabetic macular edema.
Topics: Aptamers, Nucleotide; Diabetic Retinopathy; Fluorescein Angiography; Humans; Macular Edema; Tomography, Optical Coherence; Vascular Endothelial Growth Factor A | 2009 |
Anti-vascular endothelial growth factor agents for diabetic maculopathy.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Diabetic Retinopathy; Evidence-Based Medicine; Humans; Macular Edema; Ranibizumab; Treatment Outcome; Vascular Endothelial Growth Factor A | 2010 |
Antiangiogenic therapy with anti-vascular endothelial growth factor modalities for diabetic macular oedema.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Diabetic Retinopathy; Humans; Macular Edema; Randomized Controlled Trials as Topic; Triamcinolone; Vascular Endothelial Growth Factor A | 2009 |
[Retinal vein occlusion: anti-VEGF treatments].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Blood-Retinal Barrier; Clinical Trials as Topic; Humans; Macular Edema; Prospective Studies; Ranibizumab; Retinal Vein Occlusion; Retrospective Studies; Treatment Outcome; Triamcinolone Acetonide; Vascular Endothelial Growth Factor A; Visual Acuity | 2009 |
Selective and pan-blockade agents in the anti-angiogenic treatment of proliferative diabetic retinopathy: a literature summary.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Diabetic Retinopathy; Humans; Macular Edema; Ranibizumab; Retinal Neovascularization; Vascular Endothelial Growth Factor A | 2010 |
[Diabetic maculopathy. Diagnosis and treatment].
Topics: Angiogenesis Inhibitors; Anti-Inflammatory Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Combined Modality Therapy; Diabetic Retinopathy; Fluorescein Angiography; Glycated Hemoglobin; Humans; Intravitreal Injections; Ischemia; Laser Coagulation; Macular Edema; Ophthalmoscopy; Randomized Controlled Trials as Topic; Ranibizumab; Retinal Detachment; Tomography, Optical Coherence; Triamcinolone Acetonide; Vascular Endothelial Growth Factor A | 2010 |
[Anti-VEGF inhibitors and their role in the treatment of diabetic macular oedema].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Blood-Retinal Barrier; Capillary Permeability; Clinical Trials as Topic; Combined Modality Therapy; Diabetic Retinopathy; Fluorescein Angiography; Humans; Intravitreal Injections; Laser Coagulation; Macular Edema; Middle Aged; Off-Label Use; Ranibizumab; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Retinoscopy; Triamcinolone; Vascular Endothelial Growth Factor A | 2010 |
Anti-vascular endothelial growth factor for macular edema secondary to central retinal vein occlusion.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Humans; Macular Edema; Randomized Controlled Trials as Topic; Ranibizumab; Retinal Vein Occlusion; Vascular Endothelial Growth Factor A | 2010 |
Vascular endothelial growth factor inhibitors (anti-VEGF) in the management of diabetic macular oedema: a systematic review.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Diabetic Retinopathy; Humans; Intravitreal Injections; Macular Degeneration; Macular Edema; Randomized Controlled Trials as Topic; Ranibizumab; Retreatment; Treatment Outcome; Vascular Endothelial Growth Factor A; Visual Acuity | 2012 |
Clinical development of new treatments for diabetic macular oedema.
Topics: Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Cataract Extraction; Dexamethasone; Diabetic Retinopathy; Humans; Laser Coagulation; Macular Edema; Pregnadienetriols; Tomography, Optical Coherence; Triamcinolone Acetonide | 2012 |
Anti-vascular endothelial growth factor drug treatment of diabetic macular edema: the evolution continues.
Topics: Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Blood-Retinal Barrier; Capillary Permeability; Cell Proliferation; Diabetic Retinopathy; Endothelial Cells; Female; Humans; Hyperglycemia; Intravitreal Injections; Macular Edema; Male; Oxidative Stress; Ranibizumab; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Vascular Endothelial Growth Factors | 2012 |
Biological, preclinical and clinical characteristics of inhibitors of vascular endothelial growth factors.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Diabetic Retinopathy; Humans; Macular Degeneration; Macular Edema; Ranibizumab; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Vascular Endothelial Growth Factor A | 2012 |
Diabetic macular edema.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Diabetic Retinopathy; Humans; Macular Edema; Ranibizumab; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Vascular Endothelial Growth Factor A | 2012 |
Comparative effectiveness of anti-growth factor therapies for diabetic macular edema: summary of primary findings and conclusions.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Comparative Effectiveness Research; Diabetic Retinopathy; Drug Costs; Evidence-Based Medicine; Humans; Intravitreal Injections; Macular Edema; Off-Label Use; Ranibizumab; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; United States; Vascular Endothelial Growth Factor A | 2012 |
Evidence for anti-VEGF treatment of diabetic macular edema.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Diabetic Retinopathy; Humans; Macular Edema; Ranibizumab; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Vascular Endothelial Growth Factor A | 2012 |
Anti-vascular endothelial growth factor pharmacotherapy for diabetic macular edema: a report by the American Academy of Ophthalmology.
Topics: Academies and Institutes; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Diabetic Retinopathy; Humans; Intravitreal Injections; Macular Edema; Ophthalmology; Ranibizumab; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Technology Assessment, Biomedical; Treatment Outcome; United States; Vascular Endothelial Growth Factor A | 2012 |
Antiangiogenic therapy with anti-vascular endothelial growth factor modalities for diabetic macular oedema.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Diabetic Retinopathy; Humans; Laser Coagulation; Macular Edema; Randomized Controlled Trials as Topic; Ranibizumab; Triamcinolone; Vascular Endothelial Growth Factor A | 2012 |
Anti-VEGF aptamer (pegaptanib) therapy for ocular vascular diseases.
Topics: Aptamers, Nucleotide; Clinical Trials as Topic; Diabetes Complications; Humans; Macular Degeneration; Macular Edema; Retinal Degeneration; Treatment Outcome; Vascular Endothelial Growth Factor A | 2006 |
10 trial(s) available for almagate and Macular Edema
Article | Year |
---|---|
[Japan phase 3 study of pegaptanib sodium in patients with diabetic macular edema].
Topics: Aged; Aptamers, Nucleotide; Diabetic Retinopathy; Female; Humans; Intravitreal Injections; Macular Edema; Male; Treatment Outcome | 2014 |
Pegaptanib sodium for macular edema secondary to central retinal vein occlusion.
Topics: Angiogenesis Inhibitors; Aptamers, Nucleotide; Double-Blind Method; Female; Fluorescein Angiography; Humans; Injections; Macular Edema; Male; Middle Aged; Retinal Vein Occlusion; Tonometry, Ocular; Vascular Endothelial Growth Factor A; Visual Acuity; Vitreous Body | 2009 |
[Initial and unique treatment of macular edema due to branch retinal vein occlusion with antiangiogenic agents. A comparative pilot study].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Follow-Up Studies; Humans; Macular Edema; Pilot Projects; Ranibizumab; Retinal Vein Occlusion; Tomography, Optical Coherence; Treatment Outcome; Visual Acuity | 2009 |
Pegaptanib sodium for macular edema secondary to branch retinal vein occlusion.
Topics: Aged; Aged, 80 and over; Aptamers, Nucleotide; Female; Humans; Injections; Macular Edema; Male; Middle Aged; Prospective Studies; Retina; Retinal Vein Occlusion; Tomography, Optical Coherence; Treatment Outcome; Vascular Endothelial Growth Factor A; Visual Acuity; Vitreous Body | 2010 |
A phase 2/3, multicenter, randomized, double-masked, 2-year trial of pegaptanib sodium for the treatment of diabetic macular edema.
Topics: Adult; Aged; Aged, 80 and over; Aptamers, Nucleotide; Diabetic Retinopathy; Dose-Response Relationship, Drug; Female; Fluorescein Angiography; Fundus Oculi; Humans; Intravitreal Injections; Macula Lutea; Macular Edema; Male; Middle Aged; Treatment Outcome; Vascular Endothelial Growth Factor A; Visual Acuity; Young Adult | 2011 |
Changes in vision- and health-related quality of life in patients with diabetic macular edema treated with pegaptanib sodium or sham.
Topics: Adult; Aged; Aged, 80 and over; Aptamers, Nucleotide; Diabetic Retinopathy; Double-Blind Method; Female; Humans; Macular Edema; Male; Middle Aged; Quality of Life; Sickness Impact Profile; Surveys and Questionnaires; Tomography, Optical Coherence; Treatment Outcome; Vision, Ocular; Visual Acuity; Young Adult | 2011 |
Prophylaxis of pseudophakic cystoid macular edema with intraoperative pegaptanib.
Topics: Aged; Aged, 80 and over; Aptamers, Nucleotide; Female; Follow-Up Studies; Hospitals, University; Humans; Intravitreal Injections; Macular Edema; Male; Phacoemulsification; Pilot Projects; Prospective Studies; Pseudophakia; Spain; Tomography, Optical Coherence; Treatment Outcome | 2012 |
Psychometric validation of the Visual Function Questionnaire-25 in patients with diabetic macular edema.
Topics: Adult; Aged; Aged, 80 and over; Aptamers, Nucleotide; Diabetic Retinopathy; Double-Blind Method; Female; Humans; Interviews as Topic; Macular Edema; Male; Middle Aged; Psychometrics; Reproducibility of Results; Sensitivity and Specificity; Surveys and Questionnaires; Vision, Ocular; Young Adult | 2013 |
Plasma levels of vascular endothelial growth factor before and after intravitreal injection of bevacizumab, ranibizumab and pegaptanib in patients with age-related macular degeneration, and in patients with diabetic macular oedema.
Topics: Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Diabetic Retinopathy; Enzyme-Linked Immunosorbent Assay; Female; Humans; Intravitreal Injections; Macular Edema; Male; Postoperative Period; Preoperative Period; Prospective Studies; Ranibizumab; Vascular Endothelial Growth Factor A; Wet Macular Degeneration | 2013 |
A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema.
Topics: Adult; Aged; Aged, 80 and over; Aptamers, Nucleotide; Diabetic Retinopathy; Double-Blind Method; Female; Humans; Injections; Macular Edema; Male; Middle Aged; Oligonucleotides; Safety; Tomography, Optical Coherence; Treatment Outcome; Vascular Endothelial Growth Factor A; Visual Acuity; Vitreous Body | 2005 |
23 other study(ies) available for almagate and Macular Edema
Article | Year |
---|---|
[Molecular targeting therapy for diabetic retinopathy].
Topics: Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Diabetic Retinopathy; Humans; Macular Edema; Molecular Targeted Therapy; Ranibizumab; Vascular Endothelial Growth Factor A | 2012 |
Efficacy and safety of the intravitreal treatment of diabetic macular edema with pegaptanib: a 12-month follow-up.
Topics: Aged; Aged, 80 and over; Aptamers, Nucleotide; Diabetic Retinopathy; Female; Follow-Up Studies; Humans; Intravitreal Injections; Macular Edema; Male; Middle Aged; Time Factors; Treatment Outcome | 2013 |
Predictors of anti-vascular endothelial growth factor treatment responses in macular edema following central vein occlusion.
Topics: Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Humans; Macular Edema; Ranibizumab; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Retinal Vein Occlusion; Vascular Endothelial Growth Factor A; Visual Acuity | 2014 |
The use of weighted health-related Quality of Life scores in people with diabetic macular oedema at baseline in a randomized clinical trial.
Topics: Aged; Aptamers, Nucleotide; Cross-Sectional Studies; Diabetic Retinopathy; Female; Humans; Macular Edema; Male; Middle Aged; Quality of Life; Randomized Controlled Trials as Topic; Receptors, Vascular Endothelial Growth Factor; Retrospective Studies; Surveys and Questionnaires; Treatment Outcome; Visual Acuity | 2015 |
[Anti-VEGF therapy to treat diabetic macular edema].
Topics: Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Diabetic Retinopathy; Humans; Macular Edema; Ranibizumab; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Vascular Endothelial Growth Factor A | 2014 |
Effect of switching therapy to pegaptanib in eyes with the persistent cases of exudative age-related macular degeneration.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Combined Modality Therapy; Drug Substitution; Exudates and Transudates; Female; Humans; Intravitreal Injections; Macular Degeneration; Macular Edema; Male; Middle Aged; Photochemotherapy; Prospective Studies; Radiography; Ranibizumab; Retina; Retinal Detachment; Tomography, Optical Coherence; Treatment Failure; Visual Acuity | 2014 |
The effect of pegaptanib (Macugen(®) ) injection on retinal and retrobulbar blood flow in retinal Ischaemic diseases.
Topics: Adult; Aged; Angiogenesis Inhibitors; Aptamers, Nucleotide; Blood Flow Velocity; Diabetic Retinopathy; Female; Humans; Injections, Intraocular; Ischemia; Laser-Doppler Flowmetry; Macular Edema; Male; Middle Aged; Prospective Studies; Retinal Artery; Retinal Vein Occlusion; Ultrasonography, Doppler, Color; Vascular Endothelial Growth Factor A | 2015 |
Treatment Patterns of Anti-Vascular Endothelial Growth Factor and Laser Therapy Among Patients with Diabetic Macular Edema.
Topics: Adolescent; Adult; Angiogenesis Inhibitors; Aptamers, Nucleotide; Bevacizumab; Cohort Studies; Diabetic Retinopathy; Female; Humans; Laser Therapy; Logistic Models; Macular Edema; Male; Middle Aged; Ranibizumab; Retrospective Studies; Treatment Outcome; Vascular Endothelial Growth Factor A; Young Adult | 2015 |
Pegaptanib sodium for acute retinal necrosis-induced macular oedema.
Topics: Adult; Angiogenesis Inhibitors; Aptamers, Nucleotide; Female; Humans; Injections; Macular Edema; Retinal Necrosis Syndrome, Acute; Tomography, Optical Coherence; Vascular Endothelial Growth Factor A; Visual Acuity; Vitreous Body | 2010 |
[Intravitreous injection: retrospective study on 2028 injections and their side effects].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Cataract; Diabetic Retinopathy; Endophthalmitis; Epiretinal Membrane; Humans; Injections; Macular Degeneration; Macular Edema; Ocular Hypertension; Ranibizumab; Retinal Detachment; Retinal Perforations; Retinal Vein Occlusion; Retrospective Studies; Risk Assessment; Triamcinolone Acetonide; Vitreous Body; Vitreous Hemorrhage | 2008 |
Safety monitoring with ocular anti-vascular endothelial growth factor therapies.
Topics: Aptamers, Nucleotide; Diabetic Retinopathy; Humans; Macular Degeneration; Macular Edema; Vascular Endothelial Growth Factors | 2008 |
Anti-VEGF therapeutic approaches for diabetic macular edema.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Diabetic Retinopathy; Disease Models, Animal; Humans; Injections; Macular Edema; Ranibizumab; Treatment Outcome; Vascular Endothelial Growth Factor A; Vitreous Body | 2009 |
[Macular thickness might be a recurrence probability predictor in macular edema due to retinal vein occlusions treated with repeated intravitreal injections of antiangiogenics].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Drug Monitoring; Humans; Injections; Macula Lutea; Macular Edema; Prognosis; Ranibizumab; Recurrence; Retinal Vein Occlusion; Vitreous Body | 2009 |
Intravitreal pegaptanib sodium (Macugen) for diabetic macular oedema.
Topics: Aged; Aged, 80 and over; Aptamers, Nucleotide; Diabetic Retinopathy; Eyeglasses; Female; Follow-Up Studies; Fovea Centralis; Humans; Injections; Macula Lutea; Macular Edema; Male; Middle Aged; Photoreceptor Cells, Vertebrate; Retrospective Studies; Tomography, Optical Coherence; Vascular Endothelial Growth Factor A; Visual Acuity; Vitreous Body | 2009 |
Pegaptanib for branch retinal vein occlusion.
Topics: Aptamers, Nucleotide; Humans; Injections; Macular Edema; Retina; Retinal Vein Occlusion; Tomography, Optical Coherence; Treatment Outcome; Vascular Endothelial Growth Factor A; Visual Acuity; Vitreous Body | 2010 |
Antivascular endothelial growth factor in diabetic retinopathy.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Diabetic Retinopathy; Humans; Macular Edema; Ranibizumab; RNA, Small Interfering; Sirolimus; Vascular Endothelial Growth Factor A | 2010 |
Pegaptanib octasodium for the treatment of diabetic macular edema.
Topics: Aptamers, Nucleotide; Clinical Trials, Phase II as Topic; Diabetic Retinopathy; Humans; Macular Edema; Vascular Endothelial Growth Factor A | 2011 |
[Complications of intravitreal injections--own experience].
Topics: Aged; Anti-Inflammatory Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Conjunctival Diseases; Diabetic Retinopathy; Endophthalmitis; Eye Diseases; Eye Hemorrhage; Female; Follow-Up Studies; Glucocorticoids; Humans; Inflammation; Intravitreal Injections; Iris Diseases; Macular Degeneration; Macular Edema; Male; Middle Aged; Ocular Hypertension; Poland; Ranibizumab; Retinal Diseases; Retinal Vein Occlusion; Retrospective Studies; Risk Factors; Triamcinolone Acetonide; Visual Acuity | 2011 |
Lamellar macular hole following intravitreal pegaptanib sodium (Macugen) injection for diabetic macular edema.
Topics: Aged; Aptamers, Nucleotide; Diabetic Retinopathy; Female; Humans; Intravitreal Injections; Macular Edema; Retinal Perforations; Vascular Endothelial Growth Factor A | 2011 |
Intravitreal pegaptanib sodium (Macugen®) for treatment of diabetic macular oedema: a morphologic and functional study.
Topics: Aged; Aptamers, Nucleotide; Color Perception; Color Perception Tests; Diabetic Retinopathy; Female; Fovea Centralis; Humans; Intravitreal Injections; Longitudinal Studies; Macular Edema; Male; Middle Aged; Tomography, Optical Coherence; Treatment Outcome; Vascular Endothelial Growth Factor A; Visual Acuity | 2012 |
Changes in retinal neovascularization after pegaptanib (Macugen) therapy in diabetic individuals.
Topics: Adult; Aged; Aged, 80 and over; Aptamers, Nucleotide; Diabetic Retinopathy; Female; Fluorescein Angiography; Humans; Injections; Macular Edema; Male; Middle Aged; Randomized Controlled Trials as Topic; Retinal Neovascularization; Retrospective Studies; Vascular Endothelial Growth Factor A; Visual Acuity; Vitreous Body | 2006 |
Intravitreal pegaptanib sodium (Macugen) for refractory cystoid macular edema in pericentral retinitis pigmentosa.
Topics: Acetazolamide; Administration, Oral; Adult; Aptamers, Nucleotide; Carbonic Anhydrase Inhibitors; Drug Resistance; Fundus Oculi; Humans; Macular Edema; Male; Retinitis Pigmentosa; Retreatment; Tomography, Optical Coherence; Visual Field Tests; Vitreous Body | 2009 |
Intravitreal pegaptanib sodium for refractory pseudophakic macular oedema.
Topics: Aged; Angiogenesis Inhibitors; Aptamers, Nucleotide; Diabetic Retinopathy; Female; Fluorescein Angiography; Humans; Macular Edema; Male; Middle Aged; Prospective Studies; Pseudophakia; Tomography, Optical Coherence; Treatment Outcome; Vitrectomy | 2008 |